A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Inclusion Criteria:

• Diagnosis of discoid/subacute cutaneous lupus erythematosus (DLE/SCLE) for at least 3 months prior to screening visit

• Meets both clinical and histopathological diagnostic cutaneous lupus erythematosus (CLE) criteria per protocol

• Currently receiving treatment for DLE/SCLE with a stable regimen of at least one ofthe following medications: oral corticosteroid, and/or antimalarial, and/orimmunosuppressant

• Participant could be with or without concurrent systemic lupus erythematosus (SLE)

• If participant receives nonsteroidal anti-inflammatory drugs (NSAIDs) or analgesicstreatment then the participant must be on a stable dose 2 weeks prior to screening

Exclusion Criteria:

• Women who are pregnant, lactating, breastfeeding or planning pregnancy during thestudy period

• Any of the following specific CLE subtypes in isolation: acute cutaneous lupuserythematosus (ACLE), lupus tumidus, lupus (profundus) panniculitis, chilblains

• Drug-induced CLE and/or drug-induced systemic lupus erythematosus (SLE)

• Antiphospholipid antibody syndrome, serious thrombotic event or unexplainedpregnancy loss within 1 year before the screening visit

• History of 3 or more unexplained consecutive pregnancy losses

• Active severe or unstable neuropsychiatric SLE

• Other autoimmune diseases or non-SLE driven inflammatory joint or skin disease oroverlap syndromes as primary disease that in the opinion of the investigator willsignificantly impact the assessment of CLE/SLE disease manifestations and activity

Other protocol-defined inclusion/exclusion criteria apply